The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Molecular footprints of human lung cancer progression
Open accessAbstract
Lung cancer is the leading cause of cancer‐related death in the world. To understand the molecular processes and pathways of, and contributing factors to lung cancer progression, genetic alterations in various progression stages of lung cancer cells have been studied, since these alterations can be regarded as molecular footprints representing the individual processes of multistage lung carcinogenesis. The results indicate that defects in both the p53 and RB/p16 pathways are essential for the malignant transformation of lung epithelial cells. Several other genes, such as K‐ras, PTEN and MYO18B, are genetically altered less frequently than p53 and RB/p16 in lung cancer cells, suggesting that alterations in these genes are associated with further malignant progression or unique phenotypes in a subset of lung cancer cells. However, it is still unclear what genes control the metastatic potential of lung cancer cells. Further analyses of molecular footprints in lung cancer cells, in particular in the cells of metastatic sites, will give us valuable information to fully understand the process of lung cancer progression, and to find novel ways of controlling it. Molecular footprints at the sites of p53 mutations and p16 deletions further indicate that DNA repair activities for G:C to T:A transversion and non‐homologous end‐joining of DNA double‐strand breaks play important roles in the accumulation of genetic alterations in lung cancer cells. Thus, identification of environmental as well as genetic factors inducing or suppressing the occurrence of such alterations would be a clue to find novel ways of lung cancer prevention.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“KRAS mutations are often early events in tumourigenesis in lung and pancreatic cancers [41, 42].”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [41]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
A multigenic program mediating breast cancer metastasis to bone
Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Käkönen, S.-M., Cordon‐Cardo, C., Guise, T. A., & Massagué, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00132-6 · Cited by 2,605
A molecular signature of metastasis in primary solid tumors
Ramaswamy, S., Ross, K. N., Lander, E. S., & Golub, T. R. (2002) · Nature Genetics · doi:10.1038/ng1060 · Cited by 2,469
Metastasis genes: A progression puzzle
Bernards, R., & Weinberg, R. A. (2002) · Nature · doi:10.1038/418823a · Cited by 801
Schmidt‐Kittler, O., Ragg, T., Daskalakis, A., Granzow, M., Ahr, A., Blankenstein, T. J. F., Kaufmann, M., Diebold, J., Arnholdt, H., Müller, P. E., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1331931100 · Cited by 637
The genetics and genomics of cancer
Balmain, A., Gray, J. W., & Ponder, B. A. J. (2003) · Nature Genetics · doi:10.1038/ng1107 · Cited by 582
Bartsch, H., Nair, U., Risch, A., Rojas, M., Wikman, H., & Alexandrov, K. (2000) · PubMed · Cited by 569
Minna, J. D., Roth, J. A., & Gazdar, A. F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00027-2 · Cited by 567
Tumor progression and metastasis
Yokota, J. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.497 · Cited by 435
Self-citationTumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers
Zabarovsky, E. R., Lerman, M. I., & Minna, J. D. (2002) · Oncogene · doi:10.1038/sj.onc.1205835 · Cited by 383
Hainaut, P. (2001) · Carcinogenesis · doi:10.1093/carcin/22.3.367 · Cited by 375
Yokota, J., Tsunetsugu‐Yokota, Y., Battifora, H. A., Fevre, C. L., & Cline, M. J. (1986) · Science · doi:10.1126/science.3941898 · Cited by 371
Self-citationClinical significance of ras oncogene activation in human lung cancer
Therapy, E. (1993) · Lung Cancer · doi:10.1016/0169-5002(93)90536-7 · Cited by 361
Altered methylation patterns in cancer cell genomes: Cause or consequence?
Baylin, S. B., & Bestor, T. H. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00061-2 · Cited by 278
hOGG1 Ser326Cys polymorphism and lung cancer susceptibility.
Sugimura, H., Kohno, T., Wakai, K., Nagura, K., Genka, K., Igarashi, H., Morris, B., Baba, S., Ohno, Y., Gao, C., et al. (1999) · PubMed · Cited by 235
Self-citationThe XRCC1 399 glutamine allele is a risk factor for adenocarcinoma of the lung
Divine, K. K., Gilliland, F. D., Crowell, R. E., Stidley, C. A., Bocklage, T. J., Cook, D. L., & Belinsky, S. A. (2001) · Mutation Research/DNA Repair · doi:10.1016/s0921-8777(00)00059-8 · Cited by 220
The p53 codon 72 polymorphism and lung cancer risk.
Fan, R., Wu, M., MILLER, D. P., Wain, J. C., Kelsey, K. T., Wiencke, J. K., & Christiani, D. C. (2000) · PubMed · Cited by 183
Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines.
Shapiro, G. I., Park, J. E., Edwards, C. D., Mao, L., Merlo, A. U., Sidransky, D., Ewen, M. E., & Rollins, B. J. (1995) · PubMed · Cited by 181
Kaye, F. J. (2002) · Oncogene · doi:10.1038/sj.onc.1205834 · Cited by 153
The p53 network in lung carcinogenesis
Robles, A. I., Linke, S. P., & Harris, C. C. (2002) · Oncogene · doi:10.1038/sj.onc.1205563 · Cited by 138
Frequent allelic losses on chromosomes 2q, 18q, and 22q in advanced non-small cell lung carcinoma.
Shiseki, M., Kohno, T., Nishikawa, R., Sameshima, Y., Mizoguchi, H., & Yokota, J. (1994) · PubMed · Cited by 133
Self-citationContribution of the NQO1 and GSTT1 polymorphisms to lung adenocarcinoma susceptibility.
Sunaga, N., Kohno, T., Yanagitani, N., Sugimura, H., Kunitoh, H., Tamura, T., 武井, 義., Tsuchiya, S., Saito, R., & Yokota, J. (2002) · PubMed · Cited by 126
Self-citationManganese Superoxide Dismutase Alanine-to-Valine Polymorphism at Codon 16 and Lung Cancer Risk
Wang, L. I., Miller, D. P., Sai, Y., Liu, G., Su, L., Wain, J. C., Lynch, T. J., & Christiani, D. C. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.23.1818 · Cited by 125
How many tumor suppressor genes are involved in human lung carcinogenesis?
Kohno, T. (1999) · Carcinogenesis · doi:10.1093/carcin/20.8.1403 · Cited by 105
Self-citationJohnson, B. E., Battey, J. F., Linnoila, I. R., Becker, K. L., Makuch, R., Snider, R. H., Carney, D. N., & Minna, J. D. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112604 · Cited by 104
Nishioka, M., Kohno, T., Tani, M., Yanaihara, N., Tomizawa, Y., Otsuka, A., Sasaki, S., Kobayashi, K., Niki, T., Maeshima, A., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192445899 · Cited by 103
Self-citationEvidence emerges for early metastasis and parallel evolution of primary and metastatic tumors
Gray, J. W. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00167-3 · Cited by 102
Tomizawa, Y., Kohno, T., Fujita, T., Kiyama, M., Saito, R., Noguchi, M., Matsuno, Y., Hirohashi, S., Yamaguchi, N., Nakajima, T., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202384 · Cited by 89
Self-citationChromosome Breaks and Genomic Instability
Jasin, M. (2000) · Cancer Investigation · doi:10.3109/07357900009023065 · Cited by 87
Yokota, J., Wada, M., Yoshida, T., Noguchi, M., Terasaki, T., Shimosato, Y., Sugimura, T., & Terada, M. (1989) · Lung Cancer · doi:10.1016/0169-5002(89)90332-2 · Cited by 82
Self-citationKimura, M., Abe, T., Sunamura, M., Matsuno, S., & Horii, A. (1996) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199610)17:2 · Cited by 75
Self-citationMolecular processes of chromosome 9p21 deletions in human cancers
Sasaki, S., Kitagawa, Y., Sekido, Y., Minna, J. D., Kuwano, H., Yokota, J., & Kohno, T. (2003) · Oncogene · doi:10.1038/sj.onc.1206589 · Cited by 69
Self-citationKitagawa, Y., Inoue, K., Sasaki, S., Hayashi, Y., Matsuo, Y., Lieber, M. R., Mizoguchi, H., Yokota, J., & Kohno, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208353200 · Cited by 56
Self-citationOokawa, K., Shiseki, M., Takahashi, R., Yoshida, Y., Terada, M., & Yokota, J. (1993) · PubMed · Cited by 44
Self-citationAdachi, J.-I., Ookawa, K., Shiseki, M., Okazaki, T., Tsuchida, S., Morishita, K., & Yokota, J. (1996) · PubMed · Cited by 25
Self-citationGenetic alterations responsible for metastatic phenotypes of lung cancer cells
Yokota, J., Nishioka, M., Tani, M., & Kohno, T. (2003) · Clinical & Experimental Metastasis · doi:10.1023/a:1022978932215 · Cited by 24
Self-citationSumitomo, K., Shimizu, E., Shinohara, A., Yokota, J., & Sone, S. (1999) · International Journal of Oncology · doi:10.3892/ijo.14.6.1075 · Cited by 23
Self-citationYanagitani, N. (2002) · Carcinogenesis · doi:10.1093/carcin/23.7.1177 · Cited by 21
Metastasis: the role of chance in malignancy
Edwards, P. A. (2002) · Nature · doi:10.1038/419559b · Cited by 16
Adachi, J.-I., Ookawa, K., Kohno, T., Tomizawa, Y., Tsuchida, S., & Yokota, J. (1998) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400325 · Cited by 16
Self-citationMetastasis: objections to the same-gene model
Sherley, J. L. (2002) · Nature · doi:10.1038/419560a · Cited by 10
Yanagitani, N., Kohno, T., Kim, J.-G., Kunitoh, H., Tamura, T., 武井, 義., Tsuchiya, S., Saito, R., & Yokota, J. (2003) · PubMed · Cited by 8
Self-citationGrowth suppression of non-small cell lung carcinoma cells by the introduction of the p16(INK4A) gene
Adachi, J., Kohno, T., Baeg, G., Akiyama, T., & Yokota, J. (1997) · International Journal of Oncology · doi:10.3892/ijo.10.1.33 · Cited by 7
Self-citation
Cited by
Sorted by citations
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis
Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., Stephens, R. M., Okamoto, A., Yokota, J., Tanaka, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.01.025 · Cited by 3,023
Self-citationRas in Cancer and Developmental Diseases
Fernández‐Medarde, A., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911411084 · Cited by 1,001
Mechanisms of PTEN loss in cancer: It’s all about diversity
Garcia, V. A., Tawil, Y., Wise, H. M., & Leslie, N. R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.02.001 · Cited by 407
KRAS mutation in pancreatic cancer
Luo, J. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.003 · Cited by 360
Le Calvez, F., Mukeria, A., Hunt, J. D., Kelm, O., Hung, R. J., Tanière, P., Brennan, P., Boffetta, P., Zaridze, D. G., & Hainaut, P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0551 · Cited by 273
Metadata
- Authors
- Yokota, J., & Kohno, T.
- Affiliations
- National Cancer Center Research Institute (JP)
- Corresponding author
- Yokota, Jun
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2004-03
- Volume
- 95
- Issue
- 3
- Pages
- 197-204
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- PMC
- PMC11159118
- OpenAlex
- W2055103019
- Cited by
- 139
- References
- 45
- Citations by year
- 2025: 3 · 2024: 3 · 2023: 1 · 2022: 5 · 2021: 3 · 2020: 7 · 2019: 6 · 2018: 4 · 2017: 6 · 2016: 3 · 2015: 5 · 2014: 7 · 2013: 8 · 2012: 3
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Science (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- lung cancer progression, multistep carcinogenesis, TP53 mutation, KRAS, PTEN, metastasis, DNA repair, G:C to T:A transversions, non-homologous end joining, lung carcinogenesis, lung cancer prevention
- MeSH terms
- Lung Neoplasms, Models, Genetic, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
